Pharmacokinetics and safety profile of a novel progesterone aqueous formulation administered by the s.c. route

Gynecological Endocrinology

Volumn 29, Issue 3, 2013, Pages 205-208

  Sator, Michael ^a   Radicioni, Milko ^b   Cometti, Barbara ^c   Loprete, Luca ^b   Leuratti, Chiara ^b   Schmidl, Doreen ^d   Garhöfer, Gerhard ^d  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b Cross Research SA   (Switzerland)

^c IBSA Institut Biochimique SA   (Switzerland)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Hormone replacement therapy; Infertility; Pregnancy

Indexed keywords

PROGESTERONE;

ADULT; AGED; AQUEOUS SOLUTION; ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SAFETY; FEMALE; FEMALE FERTILITY; HUMAN; INJECTION SITE DISCOMFORT; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; PHASE 1 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF MEDICATION; SINGLE DRUG DOSE;

ABSORPTION; ADOLESCENT; ADULT; AGED; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERTILITY AGENTS, FEMALE; HALF-LIFE; HORMONE REPLACEMENT THERAPY; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; PROGESTERONE; YOUNG ADULT;

EID: 84874294852     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.736560     Document Type: Article

References (17)

1. Warren MP, Shantha S. Uses of progesterone in clinical practice. Int J Fertil Womens Med 1999;44:96-103. (Pubitemid 29228429)
2. Gibbons WE, Toner JP, Hamacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril 1998;69:96-101. (Pubitemid 28073000)
3. Tavaniotou A, Smitz J, Bourgain C, Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update 2000;6:139-148. (Pubitemid 30182295)
4. de Ziegler D, Fanchin R. Progesterone and progestins: Applications in gynecology. Steroids 2000;65:671-679.
5. Stanczyk FZ. Pharmacokinetics of progesterone administered by the oral and parenteral routes. J Reprod Med 1999;44:141-147. (Pubitemid 29116019)
6. Nahoul K, Dehennin L, Jondet M, Roger M. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas 1993;16:185-202.
7. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: A comparative study. Fertil Steril 1994;62:485-490. (Pubitemid 24273195)
8. Simon JA, Robinson DE, Andrews MC, Hildebrand JR, Rocci ML, Blake RE, Hodgen GD. The absorption of oral micronized progesterone: The effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril 1993;60:26-33. (Pubitemid 23198914)
9. Blake EJ, Norris PM, Dorfman SF, Longstreth J, Yankov VI. Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductiveaged female subjects. Fertil Steril 2010;94:1296-1301.
10. Levy T, Yairi Y, Bar-Hava I, Shalev J, Orvieto R, Ben-Rafael Z. Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. Steroids 2000;65:645-649.
11. Nillius SJ, Johansson ED. Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone. Am J Obstet Gynecol 1971;110:470-477.
12. Zoppetti G, Puppini N, Ospitali F, Fini A. Pharmaceutics, preformulation and drug delivery. J Pharmaceut Sci 2007;97:1729-1736.
13. Zoppetti G, Puppini N, Pizzuti M, Fini A, Giovani T, Comini S. Water soluble progesterone-hydroxypropyl-β-cyclodextrin complex for injectable formulations. J Incl Phenom Macrocycl Chem 2007;57:283-288.
14. Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 1986;39:489-490. (Pubitemid 16113119)
15. Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1, 20 January 2010.
16. Schuirmann DJ. Design of bioavailability/bioequivalence studies. Drug Inf J 1990;24:315-323. (Pubitemid 20329335)
17. Goletiani NV, Keith DR, Gorsky SJ. Progesterone: Review of safety for clinical studies. Exp Clin Psychopharmacol 2007;15:427-444. (Pubitemid 350102230)